IP Library Granted Patent US 12,123,814
Granted Patent B1
US 12,123,814 · App. 16/900,019 · Granted Oct 22, 2024

G- protein coupled receptor extraction formulations

Inventors: Barbara Kaboord (Oregon, WI); Joanna Geddes (Rockton, IL); Christopher Wojewodzki (Rockton, IL); Kay Opperman (Oregon, WI); Scott Meier (Byron, IL)
Assignee: Pierce Biotechnology, Inc.
G01N1/4044C07K1/145C07K14/705C07K14/723C07H3/04C07J9/00C07J41/0033G01N2001/4061
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,123,814
App. No.
16/900,019
Granted
Oct 22, 2024
Kind
B1
Abstract

Formulations for extraction and stabilization of G-Protein Coupled Receptors (GPCRs), kits and methods for their use for extracting GPCRs from biological specimens (e.g., cells and tissues), and methods for making such formulations in bulk scale are described. GPCRs extracted from cells and tissues using the described formulations remain in a functional, solubilized form over extended time periods.

Claims (46)

1. A bulk scale solution comprising a solubilized cholesterol derivative, comprising:

a maltoside-based non-ionic detergent;

a zwitterionic detergent;

a buffering agent, wherein the buffering agent is HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), MES (2-(N-morpholino)ethanesulfonic acid), HEPPs, or PIPES (piperazine-N,N′-bis(2-ethanesulfonic acid));

10-20% (w/v) of a polyol; and

about 0.15 to 0.3% (w/v) of a cholesterol derivative, wherein the concentration ratio (w/v) of the cholesterol derivative to total detergent is about 0.5 or less, and wherein the solution is at a pH of 5-8, and wherein the cholesterol derivative remains solubilized in the bulk scale solution, wherein the bulk scale solution has a volume of about 1 L to about 20 L.

2. A method of extracting a membrane protein from a cell or a tissue, comprising:

providing a sample comprising a cell or a tissue; and

incubating the sample in the solution of claim 1 , wherein the solution is in an amount sufficient to extract the membrane protein from the cell or tissue, and wherein the extracted membrane protein is solubilized in the solution.

3. The method of claim 2 , wherein the membrane protein is a G-protein coupled receptor (GPCR), and wherein the solubilized GPCR maintains functional integrity.

4. The method of claim 3 , wherein greater than 70% of the function of the GPCR is maintained when stored for 7 days at 4° C. or wherein greater than 70% of the function of the GPCR is maintained when stored for 1 month at −20° C.

5. A kit for extracting a GPCR from a cell or tissue, comprising:

a) a GPCR extraction solution, comprising:

a maltoside-based non-ionic detergent;

a zwitterionic detergent;

a buffering agent, wherein the buffering agent is HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), MES (2-(N-morpholino)ethanesulfonic acid), HEPPs, or PIPES (piperazine-N,N′-bis(2-ethanesulfonic acid));

10-20% (w/v) of a polyol; and

about 0.15 to 0.3% (w/v) of a cholesterol derivative, wherein the concentration ratio (w/v) of the cholesterol derivative to total detergent is about 0.5 or less, and wherein the solution is at a pH of 5-8, and wherein the cholesterol derivative remains solubilized in the solution; and

b) instructions for extracting the GPCR from the cell or tissue.

6. A method for preparing a solution in bulk scale according to claim 1 , wherein the solution comprises solubilized cholesterol derivative, comprising:

combining the maltoside-based non-ionic detergent and the zwitterionic detergent to provide a solution at a first temperature;

adding the buffering agent into the solution;

elevating the temperature of the solution to a second temperature, wherein the second temperature is greater than the first temperature;

mixing the cholesterol derivative into the solution at the second temperature; and

adding the polyol into the solution to provide the bulk scale solution, wherein the bulk scale solution is buffered to pH 5-8, and wherein the cholesterol derivative is solubilized in the bulk scale solution.

7. The method of claim 6 , further comprising returning the bulk scale solution to a third temperature that is less than the second temperature, wherein the cholesterol derivative is solubilized in the bulk scale solution at the third temperature.

8. The solution of claim 1 , wherein the non-ionic detergent is selected from n-dodecyl-b-D-maltopyranoside, n-octyl-β-D-maltopyranoside, n-hexyl-β-D-maltopyranoside, glyco-diosgenin, lauryl maltose neopentyl glycol, and maltose neopentyl glycol.

9. The solution of claim 1 , wherein the zwitterionic detergent is 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), cocamidopropyl hydroxysultaine, cocamidopropyl betaine, phospholipids, phosphatidylethanolamine, or phosphatidylcholine.

10. The solution of claim 1 , wherein the cholesterol derivative is an acidic cholesterol ester.

11. The solution of claim 1 , wherein the cholesterol derivative is selected from cholesteryl hemisuccinate (CHS), cholesterol α-D-glucopyranosyl-(1→4)-β-D-glucopryanoside, and 5,11,17-tris[(carboxy)methyl]-25-monomethoxytriazolo-(3α-cholesteryl)-26,27,28-trihydroxycalix[4]arene.

12. The solution of claim 1 , wherein the polyol is glycerol, sorbitol, or xylitol.

13. The solution of claim 1 , wherein the solution is at a pH of 7-7.5.

14. A solution comprising a solubilized cholesterol derivative, wherein the solution comprises:

a maltoside-based non-ionic detergent;

a zwitterionic detergent;

a buffering agent, wherein the buffering agent is HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), MES (2-(N-morpholino)ethanesulfonic acid), HEPPs, or PIPES (piperazine-N,N′-bis(2-ethanesulfonic acid));

10-20% (w/v) of a polyol; and

about 0.15 to 0.3% (w/v) of a cholesterol derivative, wherein the concentration ratio (w/v) of the cholesterol derivative to total detergent is about 0.5 or less, and wherein the solution is at a pH of 5-8, wherein the cholesterol derivative remains solubilized in the solution.

15. The solution of claim 14 , wherein the non-ionic detergent is selected from n-dodecyl-b-D-maltopyranoside, n-octyl-β-D-maltopyranoside, n-hexyl-β-D-maltopyranoside, glyco-diosgenin, lauryl maltose neopentyl glycol, and maltose neopentyl glycol.

16. The solution of claim 14 , wherein the zwitterionic detergent is selected from 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), cocamidopropyl hydroxysultaine, cocamidopropyl betaine, phospholipids, phosphatidylethanolamine, and phosphatidylcholine.

17. The solution of claim 14 , wherein the cholesterol derivative is selected from cholesteryl hemisuccinate (CHS), cholesterol α-D-glucopyranosyl-(1→4)-β-D-glucopryanoside, and 5,11,17-tris[(carboxy)methyl]-25-monomethoxytriazolo-(3α-cholesteryl)-26,27,28-trihydroxycalix[4]arene.

18. The solution of claim 14 , wherein the polyol is glycerol, sorbitol, or xylitol.

19. A method of extracting a membrane protein from a cell or a tissue, comprising:

providing a sample comprising a cell or a tissue; and

incubating the sample in the solution of claim 14 , wherein the solution is in an amount sufficient to extract the membrane protein from the cell or tissue, and wherein the extracted membrane protein is solubilized in the solution.

20. The method of claim 19 , wherein the non-ionic detergent is selected from n-dodecyl-b-D-maltopyranoside, n-octyl-β-D-maltopyranoside, n-hexyl-β-D-maltopyranoside, glyco-diosgenin, lauryl maltose neopentyl glycol, and maltose neopentyl glycol, and wherein the zwitterionic detergent is selected from 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), cocamidopropyl hydroxysultaine, cocamidopropyl betaine, phospholipids, phosphatidylethanolamine, and phosphatidylcholine.

Assignments (2)
MERGER Recorded Mar 11, 2026
From: PIERCE BIOTECHNOLOGY, INC.
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 075052/0213 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2021
From: KABOORD, BARBARA; GEDDES, JOANNA; WOJEWODZKI, CHRISTOPHER; OPPERMAN, KAY; MEIER, SCOTT
To: PIERCE BIOTECHNOLOGY, INC.
Reel/Frame 057531/0724 →
Continuity (1)
Provisional Application 62861466 · Jun 14, 2019